Using Light to Probe How the Brain Works: Three Optogenetics Pioneers Win the 2026 Nobel Prize in Medicine

When a memory surfaces or a wave of anxiety rises, which nerve cells are driving these changes? To answer such questions, researchers need more than recordings of brain activity: they must also be able to intervene precisely and observe how the results change. The 2026 Nobel Prize in Physiology or Medicine was announced on October 5 and shared by Karl Deisseroth, Peter Hegemann, and Georg Nagel, honoring discoveries that made light a tool for controlling cells.

The work of the three scientists connects a research journey from microorganisms to brain science. Hegemann and Nagel revealed the properties of channelrhodopsin as a light-controlled ion channel; Deisseroth and his collaborators developed these proteins into a method for controlling neurons. According to the optical society Optica, the three share the prize equally, with the honored work encompassing light-controlled ion channels and optogenetics.

The story began with how single-celled algae sense light. Karolinska Institutet noted that, while studying algae, Hegemann and Nagel discovered that channelrhodopsin on the cell surface opens a channel that allows charged ions to pass through when exposed to blue light. Transferring this protein into other cells also gives them the ability to respond to light, providing a key component for later neuroscience tools.

The next leap was to make this component work in nerve cells. Deisseroth’s team introduced the gene for channelrhodopsin into rat nerve cells and used blue light to trigger neural signals, publishing the results in 2005; two years later, the method was applied to the brains of living mice. As light-sensitive proteins and light-delivery technologies developed, researchers became able to select specific neurons and control their activity on a millisecond timescale.

This precision changed the questions experiments could ask. Stanford Medicine explained that electrical stimulation can readily affect nearby cells simultaneously, while drug effects are difficult to switch on or stop quickly. Optogenetics allows researchers to intervene more selectively in brain circuits and test whether the activity of a particular group of cells causes changes in behavior. Such experiments have been used to explore memory, emotions, and neural mechanisms associated with diseases such as depression and Parkinson’s disease. However, the results of interventions in animals cannot be taken directly as evidence of treatment effects in humans.

This line of research continues to expand. The European Research Council stated that Hegemann received an Advanced Grant in 2016 to continue searching for new light-sensitive proteins, with research findings including the first heterodimeric rhodopsin. A Synergy Grant project in which he has participated since 2022 aims to extend optogenetics to more biological systems. Discoveries initially made to understand algae have now also become tools for exploring the functions of different cells.

Regarding medical applications, both Karolinska Institutet and Optica mentioned that researchers are attempting to use optogenetics to help people with impaired vision regain sight. However, these prize announcements did not provide trial sizes, long-term safety information, or the scope of applicability sufficient to assess efficacy. The achievement most firmly established by this award is enabling scientists to probe more precisely how cells influence behavior and disease. How far this knowledge can take us, and how it can be translated into therapies available to patients, remain questions for clinical evidence to answer.